In an siRNA high-throughput screen of over 20,000 genes of potential BMPR2 modulators, the tumor suppressor gene Fragile Histidine Triad (FHIT) was identified and thereafter pharmaceutically targeted by the repurposed drug Enzastaurin, which reversed established experimental PH in Sugen Hypoxia rats. Here, FHIT is linked to neoplasm.